BETAKIT / Oncoustics has raised about $5.5 million CAD ($4.3 million USD) in seed funding to disrupt liver care by facilitating easier early disease detection, diagnosis, and patient management.

The Toronto and San Francisco-based startup is developing a hardware-agnostic, artificial intelligence (AI)-powered software platform designed to turn existing ultrasound devices into more powerful and efficient point-of-care diagnostic tools for liver disease and other diseases “with high unmet clinical need.”

Read the full article here